Patents Examined by Fred Reynolds
-
Patent number: 8778923Abstract: The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.Type: GrantFiled: December 12, 2012Date of Patent: July 15, 2014Assignee: Receptos, Inc.Inventors: Marcus F. Boehm, Esther Martinborough, Manisha Moorjani, Junko Tamiya, Liming Huang, Adam R. Yeager, Enugurthi Brahmachary, Thomas Fowler, Andrew Novak, Premji Meghani, Michael Knaggs
-
Patent number: 8764733Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.Type: GrantFiled: June 29, 2012Date of Patent: July 1, 2014Assignee: Rani Therapeutics, LLCInventor: Mir Imran
-
Patent number: 8759281Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.Type: GrantFiled: January 20, 2012Date of Patent: June 24, 2014Assignee: Immune Targeting Systems Ltd.Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
-
Patent number: 8753892Abstract: The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for prostate cancer, and the use of PDE4D7 as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs.Type: GrantFiled: May 11, 2010Date of Patent: June 17, 2014Assignee: Koninklijke Philips N.V.Inventors: Ralf Hoffmann, Miles Douglas Houslay, David James Peter Henderson
-
Patent number: 8742071Abstract: The present invention provides a novel nucleic acid sequence, designated LIP2, encoding a lipolytic enzyme and the corresponding encoded amino acid sequences. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding at least one novel lipolytic enzyme, recombinant lipolytic enzyme proteins and methods for producing the same.Type: GrantFiled: March 11, 2010Date of Patent: June 3, 2014Assignee: Danisco US Inc.Inventors: Brian E. Jones, William D. Grant, Shaun Heaphy, Susan Grant, Helen Rees
-
Patent number: 8741845Abstract: ClotBlock is a lyophilized fibrin hemostatic designed for use an adjunct or primary treatment in moderate to severe hemorrhage. It can be applied directly to the wound in a laparotomy procedure or as non-invasive sealant. Its crosslinking technology generates a strong and safe adhesive fibrin sealant required for high volume hemostasis. The attachment properties of the cake as well as the rapid formation of and stability of the fibrin clot ensures that a strong stable fibrin clot is formed within 1 to 5 minutes depending on the grade of the wound. The agent is safe, biocompatible, biodegradable and can be stored at room temperature for one year.Type: GrantFiled: December 31, 2012Date of Patent: June 3, 2014Assignee: Biomedica Mangement CorporationInventors: George David Falus, Leonid Medved
-
Patent number: 8741844Abstract: Use of a mutated antithrombin having substantially no activity, in particular no anticoagulant activity, possibly in association with an anticoagulant, for the preparation of a drug intended for the prevention or treatment of pathologies linked to or associated with coagulation disorders.Type: GrantFiled: July 18, 2008Date of Patent: June 3, 2014Assignee: Universite Paris-Sud XIInventors: Delphine Borgel born Botbol, Veronique Ferger born Picard, Elsa Bianchini
-
Patent number: 8735396Abstract: The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase.Type: GrantFiled: May 22, 2013Date of Patent: May 27, 2014Assignee: Pfizer Inc.Inventors: Jeffrey Allen Pfefferkorn, Anthony Lai Ling
-
Patent number: 8691756Abstract: The present application describes a method of treating a bacterial infection comprising administering to a subject in need thereof a pharmaceutically acceptable amount of a defined macrocycle compound.Type: GrantFiled: May 23, 2013Date of Patent: April 8, 2014Assignee: Novartis AGInventors: Roger Aki Fujimoto, Philipp Krastel, Matthew J. LaMarche
-
Patent number: 8691580Abstract: In an embodiment the instant invention discloses a modular composition comprising 1) an oligonucleotide; 2) one or more linkers, which may be the same or different, selected from Table 1, wherein the linkers are attached to the oligonucleotide at any 3? and/or 5? end; 3) one or more peptides, which may be the same or different, selected from SEQ ID NOs: 1-59, wherein the peptides are attached to the linkers; and optionally one or more lipids, solubilizing groups and/or targeting ligands attached to the oligonucleotide.Type: GrantFiled: April 4, 2011Date of Patent: April 8, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Jeffrey G. Aaronson, Stanley F. Barnett, René Bartz, Steven L. Colletti, Vasant R. Jadhav, Aaron A. Momose, Anthony W. Shaw, David M. Tellers, Thomas J. Tucker, Weimin Wang, Yu Yuan
-
Patent number: 8686026Abstract: The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.Type: GrantFiled: June 9, 2011Date of Patent: April 1, 2014Assignee: AbbVie Inc.Inventors: Bernd Liepold, Tina Jung, Peter Hölig, Rudolf Schroeder, Nancy E. Sever, Justin S. Lafountaine, Brent D. Sinclair, Yi Gao, Jianwei Wu
-
Patent number: 8680240Abstract: ClotFoam is a sealant and hemostatic agent for use in cases of non-compressible hemorrhage for moderate to severe bleeding. It can be applied in the operating room through laparoscopic ports, or directly over lacerated tissue in laparotomy procedures or outside the operating room through a mixing needle and/or a spray injection method following intracavitary severe trauma or surgery. Its crosslinking technology generates an adhesive scaffold that carries a fibrin sealant required for hemostasis. Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The composition is biocompatible and non-inflammatory. The invention uses fibrin monomer polymerized by a change of pH as active sealing component. The viscoelastic properties of the foam as well as the rapid formation of a fibrin clot ensure that the sealant remains at the site of application without being washed away by blood.Type: GrantFiled: November 1, 2012Date of Patent: March 25, 2014Inventor: George David Falus
-
Patent number: 8663617Abstract: The current invention relates to methods and compositions for the treatment of wounds in a mammalian subject. Particularly, the invention relates to novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation.Type: GrantFiled: October 16, 2012Date of Patent: March 4, 2014Assignee: Tufts UniversityInventor: Ira M Herman
-
Patent number: 8642555Abstract: The present invention relates to a prodrug comprising at least one cytostatic agent, wherein said prodrug is cleavable by prostate-specific antigen (PSA), a process for preparing said prodrug and a pharmaceutical composition containing said prodrug in a pharmaceutically effective amount, for use in the treatment of cancer.Type: GrantFiled: March 9, 2010Date of Patent: February 4, 2014Assignee: KTB Tumorforschungsgesellschaft mbHInventors: Felix Kratz, Andre Warnecke, Bakheet Elsadek
-
Patent number: 8642008Abstract: To provide a molecular probe for imaging of pancreatic islets. A molecular probe for use in imaging of pancreatic islets is provided. The molecular probe includes any one of the following polypeptides: polypeptides represented by the following formulae (1), (5), and (9); and polypeptides having homology with the foregoing polypeptides: Z-DLSXQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2? (1) Z-DLSKQMEEEAVRLFIEWLXNGGPSSGAPPPS-NH2? (5) B-DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2? (9) where X in the formulae (1) and (5) and B- in the formula (9) indicate that an amino group is labeled with a group represented by the formula (I) below having an aromatic ring, wherein A represents either an aromatic hydrocarbon group or an aromatic heterocyclic group, R1 represents a substituent that contains radioactive iodine, R2 represents either a hydrogen atom or a substituent different from that represented by R1, and R3 represents any one of a bond, a methylene group, and an oxymethylene group.Type: GrantFiled: August 31, 2010Date of Patent: February 4, 2014Assignees: Kyoto University, ARKRAY, Inc.Inventors: Nobuya Inagaki, Hideo Saji, Kentaro Toyoda, Hiroyuki Kimura, Yu Ogawa, Konomu Hirao, Kenji Nagakawa, Hirokazu Matsuda
-
Patent number: 8637465Abstract: The present invention relates to the use of peptides that are capable of binding to, and modulating the activity of NCAM. The peptides are peptide fragments of FGFRs. They are derived from two distinct binding sites for binding of the immunoglobulin-like module 2 of FGFR to NCAM F3 modules 1-2. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein NCAM and/or FGFRs play a prominent role.Type: GrantFiled: May 27, 2009Date of Patent: January 28, 2014Assignee: Kobenhavns UniversitetInventors: Vladimir Berezin, Elisabeth Bock, Artur Kochoyan
-
Patent number: 8637040Abstract: Peptides generated from a random library that are bound by a monoclonal antibody to Chlamydial glycolipid exoantigen (GLXA) and thus mimic this antigen are disclosed. Peptides that correspond to antigen-binding regions of an anti-idiotypic antibody (mAb2) specific for anti-GLXA antibody (Ab1) which act as molecular mimics of GLXA are also disclosed used as immunogens to induce broadly reactive genus-specific anti-chlamydial antibodies. These peptides and immunogenic DNA encoding the mAb2-like peptides, microparticle or nanoparticle formulations and other formulations of these peptides are disclosed as are methods for immunizing subjects to obtain genus-specific anti-chlamydial antibodies and to treat or prevent Chlamydia-associated or induced rheumatoid arthritis.Type: GrantFiled: September 21, 2009Date of Patent: January 28, 2014Assignee: National Institute of Health (NIH), U.S. Dept. of Health and Human Services (DHHS)Inventors: Judith Whittum-Hudson, Alan P. Hudson
-
Patent number: 8633296Abstract: A composite hydrogel comprises an amphiphilic triblock copolymer (ABA) and a loaded micelle bound by noncovalent interactions. The loaded micelle comprises a biologically active substance and an amphiphilic diblock copolymer (CD). The A blocks comprise a steroidal repeat unit (repeat unit 1) having both a backbone carbonate and a side chain bearing a steroid functional group. Each of the A blocks has a degree of polymerization of about 0.5 to about 4.0. The B block comprises a first poly(alkylene oxide) backbone. The C block comprises a second poly(alkylene oxide) backbone. The D block comprises a steroidal repeat unit (repeat unit 2) having both a backbone carbonate group and a side chain comprising a steroid functional group. The composite hydrogel is capable of controlled release of the biologically active substance.Type: GrantFiled: September 12, 2012Date of Patent: January 21, 2014Assignees: International Business Machines Corporation, Agency for Science, Technology and ResearchInventors: Daniel J. Coady, Richard A. DiPietro, Amanda C. Engler, James L. Hedrick, Ashlynn L. Lee, Shrinivas Venkataraman, Yi Yan Yang
-
Patent number: 8633151Abstract: The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.Type: GrantFiled: June 16, 2009Date of Patent: January 21, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Yeelana Shen
-
Patent number: 8618333Abstract: A compound of the general formula X-[Q-W—(CH?CH)n—(CH2)2-L]m (I) in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing group; n represents 0 or an integer of from 1 to 4; L represents a leaving group; and m represent an integer of from 1 to 8. The compounds find use in the conjugation of biological molecules.Type: GrantFiled: July 1, 2011Date of Patent: December 31, 2013Assignee: Polytherics LimitedInventor: Antony Godwin